Building a First Panel for Midlife Women

Ordering discipline is an underrated clinical skill. The temptation in preventive medicine runs toward breadth, partly because patients arriving at a longevity or concierge practice often expect it, and partly because a wide panel feels thorough. Breadth without a decision attached to each result generates findings that require explanation and change nothing.

The panel below is built on a single test: for each marker, name the decision it informs. Anything that fails that test comes off.

The core panel

Marker	Decision it informs	Reasonable interval
Apolipoprotein B	Whether to treat, and how hard, for atherosclerotic risk	Annually; sooner after a therapy change
Lipoprotein(a)	Whether this patient’s risk is structurally higher than their other markers suggest	Once in a lifetime unless assay changes
Fasting insulin with fasting glucose	Whether insulin resistance is present years before glycemia moves	Annually
HbA1c	Glycemic status and trend	Annually
High-sensitivity CRP	Whether an inflammatory contribution is present, interpreted alongside clinical context	Annually
Complete blood count	Anaemia as a driver of fatigue; hematological screen	Annually
Ferritin with transferrin saturation	Iron status, frequently abnormal with heavy perimenopausal bleeding	Annually, more often if bleeding is heavy
TSH with free T4	Thyroid disease, a routine imitator of the perimenopausal picture	Annually
Comprehensive metabolic panel	Renal and hepatic function; baseline before therapy	Annually
25-hydroxyvitamin D	Whether replacement is indicated, alongside bone risk	Annually
Blood pressure, measured properly	Cardiovascular risk, and a factor that changes materially in this window	Every visit
Anti-Müllerian hormone (AMH)	Time-to-menopause estimation, which sets the urgency of bone, cardiovascular and cognitive preparation and the timing of an MHT conversation	Any cycle day; stable across the cycle
Follicle-stimulating hormone (FSH)	Detection of primary ovarian insufficiency in women under forty-five; staging where menstrual history is uninformative (contraception, prior hysterectomy with ovaries in situ, LARC-induced amenorrhea)	Cycle days 2–5 in cycling women; any day if amenorrheic or on hormonal contraception, read cautiously
Total testosterone with SHBG, and calculated free testosterone	Baseline before any consideration of off-label testosterone therapy for hypoactive sexual desire disorder, and interpretation of androgen-sensitive symptoms	Morning draw; LC-MS/MS assay preferred where available; total-plus-SHBG with the Vermeulen calculation where it is not
Sex-hormone binding globulin (independent of testosterone)	Insulin resistance, additive to fasting insulin; low values are a hepatic warning sign years before glycemia moves	Any time, non-fasting adequate

Why apolipoprotein B belongs here specifically

Apolipoprotein B counts atherogenic particles. LDL cholesterol estimates the cholesterol those particles carry. The two diverge in exactly the patients where accuracy matters most: insulin-resistant, hypertriglyceridaemic, and metabolically active. A woman with an unremarkable LDL and a raised ApoB is carrying more atherogenic particles than her lipid panel implies, and treating from the LDL alone under-treats her.

The menopausal transition is the moment this becomes most relevant. Lipid profiles shift adversely across the transition in a way that is frequently attributed to age alone, and the shift often takes place before it registers as a threshold crossing on a standard panel.

Colleagues working in longevity medicine sometimes express surprise that ApoB is not standard in general practice, and the surprise is fair. It is also a poor reason to be dismissive. The marker is inexpensive, standardised, and interpretable, and the most useful thing a preventive clinician can do is explain why it earns its place rather than treat its absence as a failing.

Lipoprotein(a) belongs alongside it for a different reason. It is genetically determined, largely unmodifiable by lifestyle, and measured once. A raised result changes how aggressively you treat everything else and changes the conversation you have with the patient’s siblings and children.

Hormone testing, used narrowly

Hormone panels are the most over-ordered element of midlife assessment. In a woman over forty-five with characteristic symptoms and menstrual change, the diagnosis is clinical, and a hormone panel drawn on an arbitrary cycle day describes that day.

Testing earns its place in suspected primary ovarian insufficiency under forty, in an ambiguous picture where other causes need excluding, and where hormonal contraception makes cycle history uninformative.

Estradiol, drawn as a screening test in a symptomatic perimenopausal woman, is noise. Its intra-individual variability in this window is so large that a single value describes that morning, not the patient. Estradiol earns testing later — confirming suppression before initiating MHT in specific contexts, monitoring transdermal absorption, or in the workup of premature ovarian insufficiency

Progesterone, drawn without a specific ovulatory-function question, informs nothing at a first visit. DHEA-S has weak evidence for cognitive utility in midlife women and earns a slot only if adrenal insufficiency is on the differential or DHEA supplementation is being considered.

Testosterone as a baseline, not a diagnostic. Off-label testosterone therapy for postmenopausal HSDD is recommended by that same consensus statement to achieve premenopausal-female concentrations, which cannot be monitored without knowing where the patient started. and read with awareness that reference ranges for women are poor.

AMH earns its place because age alone is a blunt instrument for trajectory. It is valuable in predicting time to final menstrual period at both 24 and 36 months. The prediction is imperfect and comes with wide intervals; it does not tell a patient whether her final period is in nine months or three years. It does tell her whether she is close enough to that transition that the interventions clustered around it — bone-health preparation, aggressive cardiovascular risk reduction while endogenous estrogen protection still exists, and a considered MHT discussion belong in the next two years or the next ten.

FSH earns its place narrowly. In women under forty-five, an elevated FSH raises the question of primary ovarian insufficiency, a diagnosis whose long-term consequences for bone, cardiovascular and cognitive health justify catching it early. In women over forty-five with a symptomatic perimenopausal picture, FSH adds little and is often actively misleading, since a single value in the early transition can be anywhere. Of course the exceptions include those with a history of hormonal contraception, prior hysterectomy with ovaries retained, and amenorrhea from an intrauterine device.

What to leave off

Salivary cortisol curves, broad multi-hormone panels ordered without a question, routine food sensitivity IgG panels, and untargeted heavy metal screens generate results at a rate far exceeding their capacity to change management. Each one costs money, produces abnormal values that require explanation, and risks anchoring both clinician and patient on a finding of uncertain meaning.

The most common consequence is not harm. It is displacement, where a clinic spends its attention on an equivocal salivary cortisol curve while an ApoB of 118 sits unaddressed.

Retest intervals, and why they matter more than they seem

Short retest intervals manufacture noise. Biological variation, assay variation, and day-to-day physiological state combine to produce differences between two measurements that reflect neither improvement nor decline. A patient retested monthly will see movement, will interpret it as signal, and will make decisions on it.

Annual is right for most of this panel. Something changed deliberately, such as starting a statin or a substantive dietary change, warrants a retest at eight to twelve weeks to assess response, then a return to annual.

Reading a panel as a trajectory

A single panel tells you where a patient is. Four annual panels tell you where they are going, and the direction is usually the more actionable finding. Fasting insulin drifting from 5 to 9 over three years sits within the reference range throughout and describes something worth acting on.

Holding that view is harder than it sounds when results arrive as separate PDFs from three different laboratories with different reference ranges and different units. Longevitix was built to resolve exactly that, pulling laboratory results, prior records and intake information into a single longitudinal picture so the trend is visible without anyone reconstructing it manually. The interpretation the platform offers is traceable to the underlying values and to the evidence behind the recommendation, which is what allows a clinician to disagree with it intelligently.